Publicado: 18/11/2020

Pfizer/BioNTech say final results show vaccine 95% effective

Pfizer/BioNTech say final results show vaccine 95% effective

Washington (AFP) -

Pfizer and BioNTech said Wednesday that a completed study of their experimental Covid-19 vaccine showed it was 95 percent effective.

They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators 'within days.'

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

'The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,' said Pfizer CEO Albert Bourla.

'With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,' he added.

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on Covid-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2.

Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose.

No mRNA vaccines have ever been approved, but Anthony Fauci, the United States' top infectious disease scientist, told AFP Tuesday the technology had now 'established itself.'

Más en Zeta

¿Quieren  inscribirse?

¿Quieren inscribirse?

20 November 2020
En el Tribunal Electoral reposa la solicitud de un grupo denominado Partido Torrijista Revolucionario (PTR) que quiere iniciar su proceso de inscripción. Típico con la armónicaEl periodista Valerio Ábrego Jiménez, con motivo de las fiestas patrias, interpretó varias piezas musicales panameñas co...

La inversión extranjera, un ingrediente clave para la recuperación

ZETA, (JEAN PIERRE LEIGNADIER*).- Se ha iniciado un proceso de reapertura económica en el cual todos los sectores productivos del país deben trabajar de manera sostenida hacia la recuperación y reactivación; paralelamente hay que dar pasos firmes y certeros para fortalecer y proyectar las ventaja...

Planificación turística frente a nuevos retos y oportunidades

ZETA, (JEAN PIERRE LEIGNADIER).- Las actividades turísticas en el país reabren a partir de esta semana con el reto de reactivar este importante componente de la economía nacional. Al sector turismo le tomará más tiempo en recuperarse que otras actividades a nivel mundial; no obstante, hay que ac...

Explosivo debut al bate tuvo el novato Jordán Agrazal

ZETA, (HARMODIO ARROCHA JR).¿Qué me gustó de la apertura del torneo nacional de béisbol mayor 2020?. Lo bueno...El feroz despegue de la liga con la pólvora encendida y sobre todo buen pitcheo. A la ofensiva brilló el novato coclesano Jordán Agrazal, quien fue el héroe en el triunfo de Coclé por...

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.